Steatopygia is the state of having substantial levels of tissue on the buttocks and thighs. This build is not confined to the gluteal regions, but extends to the outside and front of the thighs, and tapers to the knee producing a curvilinear figure. The term is from the Greek stéar (στέαρ), meaning "tallow",  and pugḗ (πυγή), meaning "rump". Steatopygia, a genetic characteristic leading to increased accumulation of adipose tissue in the buttock region, is most notably (but not solely) found among the Khoisan of Southern Africa. It has also been observed among Pygmies of Central Africa and also the Andamanese people, such as the Onge tribe in the Andaman Islands. This genetic characteristic is prevalent among women but occurs to a lesser degree in men.Steatopygia would seem to have been a characteristic of a population which once extended from the Gulf of Aden to the Cape of Good Hope, from which peoples the Khoisan and Pygmies may be remnants. Among the Khoisan, it begins in infancy and is fully developed by the time of the first pregnancy.It has been suggested that this feature was once more widespread. Paleolithic Venus figurines, sometimes referred to as "Steatopygian Venus" figures, discovered from Europe to Asia presenting a remarkable development of the thighs, and even the  prolongation of the labia minora, have been used to support this theory. Whether these were intended to be lifelike, exaggeratory, or idealistic is unclear.
Sirolimus, a compound that inhibits mTOR signalling, is being studied to treat plexiform neurofibromas.The combination of erlotinib with sirolimus was studied to treat low-grade gliomas.Early research has shown potential for using the c-kit tyrosine kinase blocking properties of imatinib to treat plexiform neurofibromas.Peginterferon alfa-2b is being studied to treat plexiform neurofibromas.Sorafenib is being studied for treatment of unresectable plexiform neurofibroma and low-grade astrocytomas.In vitro, tranilast, inhibits growth of neurofibroma cells.Gene therapy for the neurofibromin 1 gene represents the ultimate solution to preventing the cluster of maladies which are enabled by the mutation. As of 2006, therapy for NF1 tumors had not been tested due to the lack of an appropriate NF1 tumor model. See also
Malignant peripheral nerve sheath tumor
Neurofibromatosis
Neurofibromin
Genetic disorder
Watson syndrome
Proteus syndrome
RASopathy
Palisaded encapsulated neuroma
Skin lesion
List of cutaneous conditions

References
External links

DermAtlas 67
"Neurofibroma" at Dorlands Medical Dictionary
Ferner RE, ODoherty MJ (December 2002). "Neurofibroma and schwannoma". Current Opinion in Neurology. 15 (6): 679–684. doi:10.1097/00019052-200212000-00004. PMID 12447105. S2CID 23782923.